COMP <GO>
INDV vs EWTX // PIOTROSKI F-SCORE QUALITY
Indivior Pharmaceuticals Inc. (NASDAQ) VS. Edgewise Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: INDV 9
— EWTX 2
▲ PIOTROSKI F-SCORE QUALITY LEADER: INDV
LAST: $35.37 (+0.34%) • MKT CAP: $4.17B
piotroski-score
5/9
LAST: $38.11 (-2.03%) • MKT CAP: $4.22B
piotroski-score
3/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDV VS. EWTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDV | EWTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 62.20% | -31.90% | +94.10 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | -3.41% | +1.17 | INDV | /fcf-yield <GO> |
| Operating Margin | 21.10% | -16.20% | +37.30 | INDV | /operating-margins <GO> |
| Net Profit Margin | 16.90% | 0.00% | +16.90 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | -1.10% | +5.40 | INDV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 26.00 | -22.87 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 3/9 | +2.00 | INDV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 45.7 | +6.60 | INDV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.10 | +0.05 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 25.0x | -6.60 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.17B | $4.22B | -$49.8M | EWTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDV REV | EWTX REV | INDV GROSS % | EWTX GROSS % | INDV FCF | EWTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $535.9M | 80.2% | — | -$93.0M | -$144.1M |
| FY 2024 | $1.19B | $444.7M | 80.6% | — | $7.0M | -$110.3M |
| FY 2023 | $1.09B | $320.2M | — | — | -$349.2M | -$91.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDV // BETA 1.15
EWTX // BETA 1.10